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This review aims to compare continuous with on-demand pharmacotherapy of allergic rhinitis by
focusing on pharmacodynamic, pharmacokinetic, safety, effectiveness, cost and cost-effectiveness
considerations. A working party of experts reviewed and discussed the literature and guidelines, and
conducted a qualitative analysis of the Summary of Product Characteristics of speciﬁc medicines. With
respect to medicines, the working party limited itself to antihistamines, nasal corticosteroids and
leukotriene antagonists. Based on a review of the evidence from a multidisciplinary perspective, this
article makes pharmacotherapeutic recommendations that are easy, functional and applicable to daily
practice in primary care.
The pharmacotherapeutic evidence for continuous versus on-demand treatment of allergic rhinitis
was limited. Clearly, for corticosteroids, their mechanism of action in allergic rhinitis of reducing allergic
inﬂammation requires continuous therapy at least for the duration of symptoms. For H1-antihistamines,
some trials suggest that continuous treatment is preferable but more studies are needed to conﬁrm this
conclusion. For both H1-antihistamines and nasal corticosteroids safety data indicate that continuous
treatment may be given without fears of adverse consequences, although a distinction can be made
between the ﬁrst and the second generation antihistamines. With regard to the cost and cost-
effectiveness implications of continuous therapy versus on-demand therapy, more studies are neces-
sary before deﬁnitive conclusions may be made.
 2011 Elsevier Ltd. All rights reserved.Editorial
Guidelines for thediagnosis and treatmentof allergic rhinitishave
been developed and published. Like most guidelines they are a nice
introduction and overview but seldom can be used for our patients
without further clariﬁcationand implementation recommendations.
The guidelines talk about intermittent and persistent rhinitis andsly published article. DOI of
x: þ32 (0)16 323468.
e (G. Laekeman).
rved.allergic and non-allergic rhinitis. They even go into severity classiﬁ-
cation much like the asthma guidelines have done in the past.
However, what they do not do is talk about the ways in which
we and our patients actually use the common therapies for allergic
rhinitis: short term decongestant use, oral and nasal antihistamine
use and nasal, inhaled and oral corticosteroid use. Do you use
continuous, intermittent daily or on demand use of these medica-
tions for treatment of allergic rhinitis? Or to translate—what facts
and data canwe use to help our patients decide to use the therapies
in the best way to treat their condition?
Dr. Laekeman and colleagues have prepared a nice summary of
what is knownandnot yet knownabout theuseof all these therapies
G. Laekeman et al. / Respiratory Medicine CME 4 (2011) 51e5952for allergic rhinitis. Among his author colleagues are primary care or
general practice physicians who know how difﬁcult it is to ﬁrst
determinewhat is appropriate therapyand then how to best educate
patients so they can use the therapies to their greatest advantage.
Educational objectives
 Understand the classiﬁcation of intermittent and persistent
rhinitis and how it may affect therapy selection.
 Understand the impact of rhinitis on citizen’s of the world
 Understand how therapies can be selected and combined to
provide the greatest therapeutic beneﬁt based on disease
classiﬁcation.1. Introduction
Anestimated20e30%of theadultpopulation in thewesternworld
is affected by allergic rhinitis. According to some sources 1 out of 5
children is sensitive to inhalant common allergens. Others estimate
to over 40% the number of children suffering from this condition.1e3
Allergic rhinitis is not life-threatening and considered by many
to be a trivial disease with mild symptoms. However, sufferers tell
a different story. Assessment of the disease through both general
health questionnaires and disease speciﬁc questionnaires shows
a dramatic impairment of the quality of life and usual daily activi-
ties with the patients with more severe disease experiencing the
highest level of impairment.4 Although the presence of the symp-
toms is perceived as a disturbing element in itself, in a recent
patient survey, 85% of the patients felt that their daily activities,
particularly those relating to their professional, personal and social
life, their outdoor activities and their ability to function properly at
work or at school and their sleep were impaired either moderately
or severely.5 Furthermore, a large proportion of patients report that
their disease causes sleep disturbances, such as trouble in going to
sleep or awakening during the night andmore than 50% report that
they felt tired upon waking.5e7 In a survey performed in South
Africa in 1181 patients with allergic rhinitis, symptoms of allergic
rhinitis affected the quality of sleep in 76.6% of sufferers and for
more than a third this was every night.8
Almost 40% of children suffering from allergic rhinitis reported
that they have tomiss school due their disease.5 In addition, allergic
rhinitis can impair cognitive function and compromise learning,
placing afﬂicted children at a disadvantage. In a survey of 83
adolescents with seasonal allergic rhinitis, 78% reported that they
had difﬁculty doing schoolwork, 75% could not concentrate on
solving problems and 70% were less able to get school activities
accomplished.9 In addition, both the acquisition and application of
knowledge are slowed and short-term memory is reduced in
allergic children compared with healthy children.10
In adults, allergic rhinitis can also be a cause of both work absen-
teeism and of reduced work performance with an European survey
ﬁnding that a quarter of patientshad to take timeoffworkdue to their
disease.5 These ﬁgures were conﬁrmed in another population-
survey11 which assessed the relative impacts on work loss and
decreased productivity of allergic rhinitis and asthma in 400 adults in
Northern California. The results showed that work loss, assessed as
any partial or complete lost work days during the previous 4 weeks
due to the condition,wassimilar in the twoconditions,23% forallergic
rhinitis and 24% for asthma. However, of those personswho stayed at
work and tried to “work through” their symptoms, 36% of patients
with allergic rhinitis were less effective at their jobs compared with
19% for asthma.11 These data suggest that allergic rhinitis, which is
more commonthanasthma,mayactuallyhaveabigger impact among
those who stay at work “working through” their symptoms.As allergic rhinitis is one of the most frequent diseases
encountered in clinical practice, the cost implications to society are
enormous.12 It was calculated that in the United States in 1994,
there were 811,000 missed workdays, 4,230,000 reduced produc-
tivity days, and 824,000 school absences caused by allergic
rhinitis.13 These work and school lost days account for a signiﬁcant
economic loss (for example, indirect loss from school absenteeism
was estimated to $13,000,000). For 1996, it was calculated that the
direct ﬁnancial cost of rhinitis in the United States exceeded $3
billion and there were additional costs of $4 billion for its effect on
concomitant conditions such as asthma and otitis.14 In Germany,
the average annual cost of seasonal allergic rhinitis has been esti-
mated to be V1089 per child/adolescent and V1543 per adult15
while a study using 2002 French costing data calculated an
annual cost of V4260 per patient for allergic rhinitis of which only
2% could be attributed to direct medical costs, the remainder
constituted by workdays lost due absence from work or poor
productivity and the inability to perform usual daily activities.16
These facts justify the search for optimizing the pharmaco-
therapy of allergic rhinitis. The main objective of this review is to
ﬁnd an answer to the research question: what is the pharmaco-
therapeutic evidence supporting continuous treatment of allergic
rhinitis in comparisonwith an on-demand regimen? The purpose is
to make recommendations applicable to daily practice. The
recommendations should be easy and functional to primary care.
They must be based upon a multidisciplinary approach.2. Methodological considerations
In order to make a multidisciplinary approach, a working party
with experts in the ﬁeld of pharmacology, pharmacokinetics,
pharmacotherapy, pharmaco-epidemiology and pharmacoeco-
nomics was formed.
The activities of the working party had to yield a draft paper
containing: (a) a survey of evidence and expert opinions; (b) an
identiﬁcation of the knowledge gaps; (c) a summary of the ﬁndings
and recommendations; (d) a proposal for future research initiatives.
To reach the objectives ﬁve physical meetings of the working
party took place over a period of 18 months to discuss the evidence
on these questions.
During the ﬁrst meeting a concept paper was discussed. The
outcomes of this meeting were deﬁned as actions: (a) eachmember
should have taken a task according to the concept agreed upon; (b)
a time schedule for delivering draft working papers. During the
second meeting the ﬁrst draft papers were discussed and a time
schedule was accepted to deliver a second draft. During the third
meeting a schedule of amanuscript for publicationwas agreedupon,
starting from the draft papers. Because the working papers were
mostly quite extensive, limits had to be set of what could be incor-
porated. The fourthmeetingwas organised in order to comment the
ﬁrst draft of the manuscript. The ﬁfth meeting was the decisive one
with regard to the content of the manuscript. From that time on the
emostly formal e ﬁnalising was left to one principal author.
The members of the working party reviewed the literature and
guidelines, and conducted a qualitative analysis of the Summary of
Product Characteristics (SmPC) of speciﬁc medicines. The working
party limited itself to antihistamines, nasal corticosteroids and
leukotriene antagonists as the therapeutic agents and considered
the following questions:
 What is the clinical approach used at present with regard to
continuous or ‘on-demand’ therapy?
 Do pharmacokinetic and pharmacodynamic considerations
indicate a preference for continuous or ‘on-demand’ therapy?
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between continuous versus ‘on-demand’ therapy?
 What are the cost and cost-effectiveness implications of
continuous therapy versus ‘on-demand’ therapy?
Cochrane reviews, Web of Science, PubMed and International
Pharmaceutical Abstracts were used as scientiﬁc databases. The
following search terms were all or not combined: allergic, allergy,
antihistamine, antileukotrienes, atopic, beneﬁt, congestion, corti-
costeroids, cost, continuous, decision, duration, guideline, kinetic,
leukotriene, nasal, on-demand, outcome, pharmacoeconomic,
pharmacology, risk, side effects, sneezing, steroids, symptomatic,
symptoms, therapeutic, therapy.
When selecting the studies, special attention was paid to the
continuous versus on-demand concept and the duration of therapy.
Searches weremade in parallel with different search terms as entry.
The outcomes of these searches were discussed during the meet-
ings of the working party and selection of references was made by
consensus.
This study was carried out as part of the Supportive Initiatives
for the Global Management of Allergy (SIGMA) of the UCB Institute
of Allergy.3. What is the clinical approach used at present with regard
to continuous or ‘on-demand’ therapy?
The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines
in 200317 and updated most recently in 200818 were the ﬁrst to
recommend an international approach to the treatment of allergic
rhinitis. According to these guidelines ﬁrst line treatment of allergic
rhinitis consists of three steps:
1. oral or intranasal H1-antihistamines with limited use of
decongestants for mild intermittent rhinitis
2. oral or intranasal H1-antihistamines or intranasal corticoste-
roids with limited use of decongestants and chromones for
moderate-to-severe intermittent and mild rhinitis
3. intranasal corticosteroids with step-down and step-up options,
in conjunction with H1-antihistamines, nasal decongestants,
ipratropium and oral corticosteroids for moderate-to-severe
persistent rhinitis
The three-step approach seems easy to put into practice. But as
clear-cut it may be, some considerations have to be made with
regard to symptoms and co-pathology. In the ARIA guidelines
special attention is given to co-morbidities, as allergic inﬂamma-
tion does not limit to the nasal airway. In case allergic rhinitis is
accompanied by asthma, the inhaled therapy becomes continuous
as from GINA step 2. In case the allergic rhinitis is not complicated
by any co-morbidity, the level of severity should be taken into
account when making the therapeutic approach. Starting from the
symptoms a pharmacological management can be proposed,
according to the ARIA guidelines.
 Sneezing: intranasal corticosteroids, oral or intranasal antihista-
mines.
 Rhinorrhea: intranasal corticosteroids, oral or intranasal anti-
histamines, nasal anticholinergics.
 Nasal obstruction: oral decongestants, intranasal corticoste-
roids, antileukotrienes.
 Nasal itching: oral ornasal antihistamines, nasal corticosteroids.
 Eye symptoms: intraocular antihistamines, oral antihista-
mines, intranasal corticosteroids, intraocular chromones,
antileukotrienes.Of the above-mentioned medicines, oral decongestants should
be used for a few days, especially in patients with cardiovascular co-
morbidity, benign prostate hyperplasia, sleep disturbances and
glaucoma.17
For mild intermittent rhinitis, the treatment should be when
necessary and of short duration. For moderate-to-severe intermit-
tent, the treatment should be continued to prevent the develop-
ment of persistent rhinitis. For persistent rhinitis, continuous
treatment is considered asmore efﬁcient than ‘on-demand’ therapy.
Antihistamines and intranasal corticosteroids are perceived as
being more effective if the therapy is continuous.19
The analysis of the SmPC of 24 medicines revealed that, apart
from the leukotriene antagonists and some oral glucocorticoids, all
other medicines contained the labelling ‘allergic rhinitis’ or ‘allergic
conditions of the respiratory tract’. Symptomatic as well as
prophylactic and chronic treatment is mentioned in the indications.
Divergent information is given on the duration of treatment for
different drugs:
 Oral decongestants: the duration of treatment should be as
short as possible
 H1-antihistamines: mostly no instructions with regard to
duration of therapy are given. Cetirizine and levocetirizine are
most explicit with speciﬁc durations according to the
complaints. For both products time limits are speciﬁed (e.g.
3e6 weeks for levocetirizine in case of hay fever). Most prob-
ably limited experience in clinical trials causes this warning
(SmPC dated January 2004), as for cetirizine clinical experience
covers at least one year
 Local corticosteroids: it is recommended to use the spray
‘regularly’, preventively or continuously
 Oral corticosteroids: use of betamethasone is restricted to
10e14 days
 Sodium cromoglycate: preventive treatment does not allow an
interruption of treatment4. What do we learn from clinical studies focusing on
continuous or ‘on-demand’ therapy?
4.1. H1-antihistamines
Only two studies speciﬁcally designed to compare continuous
versus on-demand therapy, both from the same research group,
were retrieved. Some comparative data were also obtained from
a third study used to assess the use of rescue medication in chil-
dren. Quantitative data from these studies are given in Table 1.
In the ﬁrst study,20 cetirizine was administered either continu-
ously or on-demand to twenty adults with seasonal allergic rhinitis
over a 4-week period of natural allergen exposure during the pollen
season. The results showed that patients treated with continuous
therapy achieved signiﬁcant symptomatic relief and inﬂammatory
control (decreases in numbers of inﬁltrating neutrophils and
eosinophils) in comparison to patients treated on-demand. Inter-
estingly, the authors comment that whereas continuous treatment
reduces clinical and inﬂammatory variables more than on-demand
therapy, the on-demand therapy can achieve acceptable clinical
control but does not reduce allergic inﬂammation. Furthermore,
the cost of therapy is lower for on-demand treatment.
The second study,21 compared two parallel groups of 31 adults
with persistent allergic rhinitis, one group taking levocetirizine
daily and the other taking it on-demand for six months. Both
treatment regimens considerably decreased the total and indi-
vidual symptom scores from baseline and achieved similar levels
up to week 14. Continuous treatment was generally better than on-
Table 1
Comparison of continuous versus on-demand therapy with cetirizine and levocetirizine.
Reference Patients Intervention Outcome
Ciprandi et al.,
1997 DBeRePl
N¼ 20 (19e48 years)
(11 men/9 women)
Rhinoconjunctivitis
due to pollen
Natural pollen exposure
Cetirizine 10 mg/day or Pl for 4
weeks C or OD Rescue
medication¼ cetirizine 10 mg/day
Nasal symptoms: C<OD: from 3rd week*
Rescue medication: C<OD: from 1st week**
Neutrophils/eosinophils: C<OD: at 4 weeks **
Cost of therapy: OD< C
Ciprandi et al.,
2001 DBeRePl
N¼ 20 (3e10 years)
(15 boys/5 girls)
Rhinoconjunctivitis
(house dust mite)
and/or mild intermittent
asthma
Cetirizine drops 5 mg/day for 24 weeks Rescue
medication¼ Cetirizine 5 mg/day Salbutamol
1 or 2 puffs of 100 mg Fluticasone 2 puffs of
125e250 mg Oral deﬂazacort 1 mg/kg AB or
acetaminophen if needed
Weekly rhinitis symptoms: C<OD: 11 weeks
on 24* Weekly asthma symptoms: C<OD:
6 weeks on 24* Additional drug intake:
C<OD 16 weeks on 24 Additional cetirizine
intake: C<OD*** Cost of therapy:
C (191.83US $)<OD (278.54US $)
Canonica et al.,
2008 ReOeP
N¼ 62 (31 in each group)
Persistent allergic rhinitis
Levocetirizine 5 mg/day for 6 months C or OD Drop out¼ 22/62 C¼OD up to week 14
C>OD from week 17 on*
The abbreviations used are: DB¼ double blind, O¼ open label, R¼ randomized, P¼ parallel, Pl¼ placebo, C¼ continuous, OD¼ on-demand, AB¼ antibiotics. Signiﬁcance
levels are indicated by; *P< 0.05, **P< 0.01, ***P< 0.001.
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from weeks 17e21 (from week 19 to 21 for nasal pruritus). Both
regimens substantially improved quality of life and sleep quality.
The authors concluded that continuous therapy showed a trend to
be more effective in controlling the symptoms of rhinitis,
improving quality of life and decreasing nasal inﬂammation
compared with on-demand therapy.
The third study22 evaluated whether cetirizine administered
regularly for 24 weeks reduced allergic symptoms and the use of
rescue medications, such as antibiotics, paracetamol, b2-agonists,
inhaled and systemic corticosteroids, in children with persistent
allergic rhinitis and asthma due to house dust mite allergy. The
results showed that symptom scores and consumption of rescue
medication were signiﬁcantly lower (P< 0.05) in the cetirizine-
treated group versus the placebo group. Furthermore, the cost of
treatment was lower with continuous therapy because more co-
medication was taken in the placebo group due to poorer
symptom control.
There is a suggestion from a small-scale studywith children that
long-term cetirizine treatment may reduce new sensitisations in
monosensitised children. The study included two groups of 10
children with mite allergy, receiving either cetirizine or placebo
daily. Cetirizine could be used as rescue medication. After six
months continuously treated children remained on cetirizine
during the following three years. The other children were treated
on-demand during the same period. After 3 years only 2 continu-
ously treated children showed polysensitization versus 5 symp-
tomatically treated children. After 6 years the results were
respectively 7 versus 9. (P¼ 0.002).23
The results of these pilot studies support the continuous use of
antihistamines as being more effective than on-demand therapy.
The observation that inﬂammatory variables, such as nasal
congestion, are suppressed better by continuous therapy supports
the hypothesis that reduction of allergic inﬂammation requires
long-term therapy with antihistamines.14,24 However, there is
a need for more clinical evidence, particularly with other antihis-
tamines. In addition, pharmacological and pharmacokinetic
parameters could help to look for a certain level of evidence. The
studies mentioned above cannot be considered as pivotal: the
number of patients per treatment group was low, especially when
placebo was included in the study design. A type 1 statistical error
(¼outcome false positive) cannot be excluded.
4.2. Nasal corticosteroids
Local administration of corticosteroids to the nose has three
primary effects: A vasoconstrictor effect which develops slowly over a period of
up to 72 h25
 A reduction of allergic inﬂammation following downregulation
of pro-inﬂammatory cytokines involved in the recruitment and
activation of inﬂammatorycells, includingeosinophils, dendritic
cells and T-lymphocytes.26,27 These effects become apparent
only slowly, taking days or evenweeks to become maximal.
 A reduction of mast cell accumulation andmaturation resulting
from the downregulation of the transcription of stem cell
factor, the primary growth factor for mast cells.28 This is the
slowest of the effects to become apparent due to the long life
span of mast cells in allergic responses.29
The ‘lag’-time before signiﬁcant therapeutic results are obtained
with intranasal corticosteroids differs from study to study being
dependent both on the glucocorticoid used and the experimental
conditions. The fastest response for signiﬁcant changes in the nasal
index score and peak nasal inspiratory ﬂow has been obtained 4 h
after the ﬁrst administration of nasal budesonide ormometasone.30
In another study31 mometasone improved the composite nasal and
non-nasal symptom score after 5 h but required 7 h to reduce nasal
symptoms.
While the above studies show that statistically signiﬁcant
improvement may occur quite rapidly, it takes much longer for
nasal corticosteroids to become truly effective. For example, by 12 h
after the ﬁrst administration of mometasone during the pollen
season, only 28% of patients experienced clinically signiﬁcant relief
28% while by 72 h 64% of the patients experienced at least
moderate relief.32 In another study, 4e8 days was needed for
signiﬁcant clinical improvement with beclomethasone and
mometasone.33 Patients onmometasone and beclomethasone have
less non minimal symptom days as compared to placebo after 2
days. The proportion of symptom free days was 83% (mometasone),
77% (beclomethasone) and 64% (placebo). The difference with
placebo was signiﬁcant for both active treatments (P< 0.01).34
In most studies with nasal corticosteroids, patients have at least
one week of treatment before the ﬁrst assessment is made.
Sometimes there is signiﬁcant relief after one week of the daytime,
but not the night-time symptoms35 Even for provocation tests, at
least two weeks pre-treatment is often given.36 Also, whether the
scoring is performed by the physician or by the patient can make
a difference. In one study,37 subjective assessments made by the
physician showed a clinical difference after one week whereas
assessments by the patients themselves required two weeks to
achieve signiﬁcant differences.
As continuous therapy with corticosteroids may reduce mast
cell numbers,38 some authors strongly recommend starting the
Table 2
Plasma T1/2 and duration of action of anti-H1-antihistamines.
Class and nonproprietary
names; I¼ 1st generation;
II¼ 2nd generation
Duration of action
(approximate
values in hours)
Plasma T1/2
(approximate
values in hours)
Ethanolamines
Diphenhydramine$HCl (I) 12 8
Alkylamines
Dexchlorpheniramine
maleate (I)
4e6 20e24
Acrivastine (II) 6e8 1.5 (Active
metabolite: 2.5)
Piperazines
Hydroxyzine$HCl (I) 6e24 20
Cetirizine.HCl (II) 12e24 8e10
Levocetirizine (II)
Phenothiazines
Promethazine$HCl (I) 4e6 10e14
Phtalazinones
Azelastine$HCl (II) 12e24 20 (Active
metabolite: 45)
Piperidines
Loratadine (II) 24 12 (active
metabolite 20)
Desloratadine (II) 24 27
Ebastine (II) 24 15e19
Mizolastine (II) 24 13
Fexofenadine (II) 12e24 11e15
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achieve a prophylactic reduction of mast cells in the nasal epithe-
lium. To this end, the SmPC for mometasone states: .The start of
the pollen season may vary, depending mainly on the geographic area
and the prevailing weather conditions, so ‘safe’ advice is to start pre-
treatment 2 to 4 weeks before start of the pollen season and to
continue treatment throughout the pollen season.. The study that
stimulated this recommendation39 was one which started admin-
istration of nasal mometasone as prophylactic treatment 2e4
weeks before the pollen season and continued for four months. An
overwhelming majority of patients (84%) were satisﬁed with this
type of treatment. There was, however, no control group, as this
was ‘a real life’ study.
Thus, with corticosteroids, which act primarily to reduce allergic
inﬂammation, continuous therapy is essential for them to be clin-
ically effective.
5. To what extent do safety considerations inﬂuence the
choice between continuous versus ‘on-demand’ therapy?
For drugs used for symptomatic relief of non-lethal conditions,
such as allergic diseases, safety is of paramount importance. As no
comparative data are available for continuous versus on-demand
therapy with respect to safety, this review will consider the long-
term safety aspects of antihistamines and intranasal corticoste-
roids in relation to their use in both situations.
5.1. H1-antihistamines
It is now over 65 years since the introduction of phenox-
ybenzamine, the ﬁrst H1-antihistamine introduced for clinical
use.40 It should be remembered that the ﬁrst-generation anti-
histamines came from the same chemical stem as anticholinergic
drugs, a stem from which tricyclic antidepressants, antipsychotics
and many other drugs were developed. Indeed, the antihistamine,
promethazine, was initially introduced as an antipsychotic drug.
As a consequence, ﬁrst-generation antihistamines are associated
with a number of adverse events, including central nervous
system depression and anticholinergic and cardiovascular effects.
Nevertheless, ﬁrst-generation H1-antihistamines, including dex-
chlorpheniramine, diphenhydramine, hydroxyzine and prom-
ethazine are still regularly used.
The introduction of terfenadine in 197841 saw the ﬁrst of the
minimally sedating H1-antihistamines, a list which now contains
many drugs including azelastine, cetirizine, desloratadine, ebastine,
fexofenadine, levocetirizine and loratadine. Second generation H1-
antihistamines are recognised as being highly effective treatments
for allergic disease and are among the most frequently prescribed
and safest drugs in the world.42 There are many second generation
H1-antihistamines available and at ﬁrst examination these appear
to be comparable in terms of safety and efﬁcacy. However, the
newer antihistamines in fact represent a heterogeneous group of
compounds, having markedly differing chemical structures,
physico-chemical properties, pharmacokinetic characteristics (e.g.
half-lives of elimination, protein binding, tissue distribution,
absolute bioavailability), being differently recognised by drug
metabolising enzymes and transporters, and producing different
adverse effects.
When comparing the duration of action with the plasma
elimination, there is not always a concordance. First-generation
antihistamines tend to have a longer plasma halﬂife as compared
to their duration of action. That is in contrast with the second
generation antihistamines where duration of action mostly
exceeds the plasma elimination halﬂife. Translated into risk-beneﬁt
it means that circulating concentrations of ﬁrst-generationantihistamines can still have secondary effects without resulting in
therapeutic beneﬁts. Respecting therapeutic regimens with ﬁrst-
generation antihistamines in order to obtain a 24 h protection
against allergic symptoms may provoke unnecessary side effects.
Theoretically the second generation of antihistamines may allow
for a continuous therapy without imposing a kinetic burden on the
patient (see Table 2). As all ﬁrst-generation antihistamines are
Over-The-Counter (OTC) medicines, it should be carefully exam-
ined which type of antihistamine should be delivered. When no
additional anticholinergic activity is wanted, second generation
antihistamines are preferable.43 The pharmacoeconomic outcome
of using ﬁrst-generation antihistamines seems to be negative by
the loss of productivity due to sedation.44
However, some other events occurred with newer substances.
The most serious toxic event reported was the association
between the consumption of astemizole or terfenadine and the
occurrence of prolongation of the QT interval, leading to the
appearance of polymorphic ventricular arrhythmias, syncope, and
even cardiac arrest.25 Both astemizole and terfenadine were
essentially pro-drugs which required hepatic ﬁrst-pass metabo-
lism by CYP3A4, a member of the hepatic cytochrome P450 family.
In most normal subjects, CYP3A4, activity was sufﬁcient to ensure
that the levels of astemizole and terfenadine in the plasma were
below the detection limits. As the cardiac adverse effects are
related directly to high plasma levels of the unmetabolised parent
drug, it follows that in patients with pre-existing cardiac
dysfunction, such as congenital QT prolongation, the presence of
impaired liver function, due to conditions such as cirrhosis or
ethanol abuse, or concomitant use of inhibitors of CYP3A4, such as
ketoconazole, itraconazole, and macrolide antibiotics, was one of
the main predisposing factors for the occurrence of cardiotox-
icity.45 Following the recognition of over 200 cases of potentially
fatal cardiac arrhythmias, both terfenadine and astemizole have
been withdrawn from the market in most countries. Finally, the
ﬁnding that an interaction with HERG1Kþ channels is the
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tially fatal cardiac arrhythmias has allowed the development of
pre-clinical tests, both in vitro and in vivo, to predict such activity.
Thus, all H1-antihistamines on the market today are free from
clinically demonstrable cardiotoxicity.
Another adverse effect of H1-antihistamines that has given
cause for concern is their potential to cause a degree of somno-
lence in some individuals, despite the relatively short plasma
elimination halﬂife (see Table 2). Most of the clinical trials report
drowsiness, sedation, or somnolence as a common adverse effect.
In a post-marketing surveillance study of fexofenadine, acrivastine,
cetirizine, and loratadine involving 43,363 people, the main
outcome measure was sedation or drowsiness.46 It found a signif-
icantly higher incidence of sedation for acrivastine (Odds Ratio
2.79, 95% CI 1.69e4.58; P< 0.0001) and cetirizine (Odds Ratio 3.53,
95% CI 2.07e5.42; P< 0.0001) compared with loratadine. However,
it found no difference between fexofenadine and loratadine (Odds
Ratio 0.63, 95% CI 0.36e1.11; P¼ 0.1). No increase in risk of accident
or injury was found with any of the four antihistamines. There
were also no considerations with regard to intermittent or
continuous use.
The majority of sedation studies with H1-antihistamines are
performed in either healthy individuals or individuals with mild
disease rather than in conditions, such as severe allergic rhinitis or
chronic urticaria, both of which cause sleep deprivation.47e49 So is
drug-induced daytime somnolence a problem with such patients.
Two studies, one with fexofenadine and the other with levocetir-
izine, found that chronic urticaria patients taking regular H1-anti-
histamine therapy experienced signiﬁcantly less interference with
sleep and improved daily activities.50,51 Two possible reasons may
be suggested to explain the decreased somnolence. The ﬁrst
possibility is the relief from physical discomfort ensuing from the
psychological status of the patients and the associated sleep
deprivation. The second possibility is the development of tolerance
to the central nervous sedative effects of the H1-antihistamines
which has been reported repeatedly to occur after 4e5 days of
administration of both ﬁrst and second generation.52e54 Thus,
although direct comparisons between continuous and on-demand
therapy with H1-antihistamines have not been performed, it is
tempting to speculate that continuous therapymay be preferable to
reduce somnolence.
An evaluation was made for azelastine (topical use) long-term
continuous treatment versus on-demand. Continuous use ach-
ieved better therapeutic outcomes, as on-demand use did not
signiﬁcantly reduce allergic inﬂammation.55
In conclusion, H1-antihistamines are very safe medicines when
taken long term. Of the major H1-antihistamines, cetirizine and
loratadine have been on the market for 20 years and desloratadine,
fexofenadine and levocetirizine for more than 8 years without
safety issues arising. In adults, formal studies of two to three
years duration have shown cetirizine to be safe when givenTable 3
Cost items of continuous/on-demand treatment of allergic rhinitis.
Direct healthcare costs
Medication Healthcare providers Other
Oral and intranasal antihistaminics General practitioner Diagnostic tes
Intranasal corticosteroids Pneumologist Immunothera
Oral and intranasal decongestants Ear, nose and throat
specialist
Accident and
Emergency vis
Intranasal anticholinergic agents Alternative m
(e.g. homeopacontinuously56,57 while in children of 1e2 years of age, both cetir-
izine and levocetirizine have been shown to be safe when given for
periods of 18 months. No serious side effects occurred over that
period. There were no signiﬁcant differences on behavioural,
cognitive or psychomotor development as compared to placebo
treated children. The tools used were: the Behavior Screening
Questionnaire, the McCarthy Scales of Children Abilities,
the General Cognitive Index and the Global Medical
Questionnaire.58e60
5.2. Nasal corticosteroids
Intranasal corticosteroids are considered relatively safe.7,38 Local
adverse effects are usually mild and include mucosal irritation and
epistaxis. Nasal septal perforation is rare. The most commonly
reported adverse effects for individual intranasal corticosteroids
are as follows:
 Beclometasone: epistaxis, upper respiratory tract infection and
headache
 Betamethasone: sore throat, ﬂushing and headache
 Budesonide: unpleasant taste, headache, coughing, nose
dryness and epistaxis
 Flunisolide: nasal burning, drowsiness, and nasal irritation
 Fluticasone: headache, epistaxis, sore throat, nasal dryness/
blowing and diarrhoea. There have been case reports of
anaphylaxis and ﬂushing as well as central nervous system,
cardiac, and dermatological reactions
 Mometasone: headache, epistaxis, and pharyngitis. In clinical
trials, the rate of treatment discontinuation with mometasone
furoate nasal spray because of adverse events was 3%, a rate
similar to those reported with placebo and active controls; the
most frequently reported adverse effects were headache, viral
infection, pharyngitis, and epistaxis
 Triamcinolone: headache, sneezing, and nasal irritation
As for the antihistamines, no comparative data are available for
continuous versus on-demand therapy. Clinical and histopatho-
logical examination of nasal mucosa after long-term intranasal
budesonide or mometasone use has failed to show signiﬁcant
changes.38 Although intranasal steroids can result in systemic
bioavailability, no signiﬁcant adverse effects have been reported on
bone metabolism. Inﬂuence of adrenal function should be consid-
ered. Based on morning salivary cortisol concentrations, for 58% of
patients on nasal betamethasone sodium phosphate and for 4% of
patients on mometasone furoate biochemical evidence of adrenal
suppression was apparent.61 Mometasone 100 mg/day does neither
inﬂuence growth in children between 3 and 9 years old, nor
interfere with the hypothalamicepituitaryeadrenocortical-axis
function. The compliance was high, but no details are given about
the therapeutic efﬁcacy.62Direct non-health care costs Indirect costs
ts Transportation to healthcare
provider
Absence from work
py Child care costs while in
treatment
Reduced productivity at work
it
Home adaptations Time lost from education
edicine
thy)
Reduced ability to carry out
usual daily activities
Fig. 1. [1] Challenge of allergic rhinitis can be multifold. Causal relationship between pollen en seasonal allergy is fading as pollen seem to penetrate into the bronchioles. [2]
Allergic rhinitis has a considerable inﬂuence on professional performance and cannot be foreseen in all circumstances. Direct as well as indirect costs play a role when considering
the interference. [3] Medicines can be prescribed according to guidelines. The prescription can have an intermittent or a continuous character. [4] Treatment can be systemic
(antihistamines, leukotriene antagonists) or local (corticosteroids, antihistamines). [5] There is a lag-time between starting the pharmacotherapy and the onset of action. [6]
Intermittent and continuous therapies are not hampered by serious side effects.
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continuous versus ‘on-demand’ therapy?
To date, no study has compared costs of continuous and on-
demand treatment of allergic rhinitis. As it is difﬁcult to deter-
mine the economic impact of allergic rhinitis, Table 3 identiﬁes
the major cost items that need to be considered when contrast-
ing costs of continuous and on-demand treatment of allergic
rhinitis from a societal perspective. In addition to direct health-
care costs, studies need to focus on eliciting direct non-
healthcare costs and indirect costs. With respect to the latter,
attention needs to be paid to calculate the indirect costs of days
lost to education and work, costs of reduced productivity at work,
and the costs of reduced ability to carry out usual daily activities.
Indirect costs need to be calculated for patients suffering from
allergic rhinitis.
One cost-effectiveness analysis investigated continuous versus
on-demand treatment in a small sample of children during six
months.22 Continuous treatment consisted of the daily adminis-
tration of cetirizine 5 mg. Alternatively, children received placebo.
However, both groups of children were allowed to use rescue or
symptomatic drugs when needed. Suggested rescue medication
was cetirizine, inhaled salbutamol, inhaled ﬂuticasone and short
courses of systemic corticosteroids. The assessment of costs was
limited to drug costs. The authors found that continuous treatment
dominated on-demand treatment: continuous treatment with
cetirizine resulted in better symptom control of allergic rhinitis and
of asthma, and in lower drug costs as compared to on-demandtreatment. There is a need for prospective economic evaluations
alongside clinical trials comparing continuous and on-demand
treatment of allergic rhinitis, with a sufﬁcient number of patients
and length of treatment period.Conclusions
This review has examined the pharmacotherapeutic evidence
for the use of continuous treatment in comparison with an on-
demand regimen (Fig. 1). Clearly, for corticosteroids, their mecha-
nism of action in allergic rhinitis of reducing allergic inﬂammation
requires continuous therapy at least for the duration of symptoms.
For H1-antihistamines the conclusion is equivocal. Some trials
suggest that continuous treatment is preferable but more studies
are needed to conﬁrm this. For both H1-antihistamines and nasal
corticosteroids safety data indicate that continuous treatment may
be givenwithout fears of adverse consequences. With regard to the
cost and cost-effectiveness implications of continuous therapy
versus on-demand therapy, more studies are necessary before
deﬁnitive conclusions may be made.
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Educational questions
1. Allergic rhinitis is estimated to affect:
a. More than 1 in 5 adults in industrialized countries
b. More about 1 in 10 adults in industrialized countries
c. More about 1 in 50 adults in industrialized countries
d. More about 1 in 100 adults in industrialized countries.
2. On demand therapy for allergic rhinitis is appropriate when
prescribing:
a. Oral or nasal decongestants
b. Oral or nasal antihistamines
c. Inhaled or nasal steroids
d. All of the above
3. On demand and intermittent use are the same.
a. True
b. False
4. For which type of therapy is on demand not physiologically
relevant?
a. Oral or nasal antihistamines
b. Oral decongestants
c. Inhaled or nasal steroidsReferences
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